LifePlan Financial LLC Cuts Stake in CVS Health Co. (NYSE:CVS)

LifePlan Financial LLC lowered its stake in CVS Health Co. (NYSE:CVS) by 4.0% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 21,063 shares of the pharmacy operator’s stock after selling 874 shares during the quarter. LifePlan Financial LLC’s holdings in CVS Health were worth $946,000 as of its most recent filing with the SEC.

Several other hedge funds have also modified their holdings of CVS. Intech Investment Management LLC grew its holdings in CVS Health by 17.1% during the 2nd quarter. Intech Investment Management LLC now owns 56,601 shares of the pharmacy operator’s stock valued at $3,343,000 after purchasing an additional 8,261 shares in the last quarter. AE Wealth Management LLC boosted its position in CVS Health by 12.3% in the 2nd quarter. AE Wealth Management LLC now owns 56,116 shares of the pharmacy operator’s stock valued at $3,314,000 after buying an additional 6,151 shares during the last quarter. Summit Trail Advisors LLC increased its position in shares of CVS Health by 33.3% during the second quarter. Summit Trail Advisors LLC now owns 14,282 shares of the pharmacy operator’s stock worth $843,000 after acquiring an additional 3,564 shares during the last quarter. ProShare Advisors LLC lifted its stake in shares of CVS Health by 9.0% in the second quarter. ProShare Advisors LLC now owns 209,881 shares of the pharmacy operator’s stock worth $12,396,000 after acquiring an additional 17,281 shares in the last quarter. Finally, Frank Rimerman Advisors LLC boosted its holdings in CVS Health by 9,318.2% in the second quarter. Frank Rimerman Advisors LLC now owns 9,324 shares of the pharmacy operator’s stock valued at $551,000 after purchasing an additional 9,225 shares during the last quarter. 80.66% of the stock is currently owned by hedge funds and other institutional investors.

CVS Health Trading Up 1.5 %

Shares of NYSE:CVS opened at $52.72 on Tuesday. The company has a quick ratio of 0.59, a current ratio of 0.80 and a debt-to-equity ratio of 0.80. The company’s 50-day moving average price is $51.27 and its 200 day moving average price is $56.29. The company has a market cap of $66.35 billion, a PE ratio of 13.38, a P/E/G ratio of 0.79 and a beta of 0.59. CVS Health Co. has a fifty-two week low of $43.56 and a fifty-two week high of $80.75.

CVS Health (NYSE:CVS) last issued its quarterly earnings data on Wednesday, November 6th. The pharmacy operator reported $1.09 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.08 by $0.01. CVS Health had a return on equity of 10.72% and a net margin of 1.36%. The business had revenue of $95.43 billion during the quarter, compared to analyst estimates of $92.72 billion. During the same period in the prior year, the company posted $2.21 EPS. The business’s revenue for the quarter was up 6.3% compared to the same quarter last year. Sell-side analysts anticipate that CVS Health Co. will post 5.22 earnings per share for the current year.

CVS Health Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, February 3rd. Shareholders of record on Thursday, January 23rd will be paid a dividend of $0.665 per share. The ex-dividend date is Thursday, January 23rd. This represents a $2.66 annualized dividend and a yield of 5.05%. CVS Health’s payout ratio is 67.51%.

Analysts Set New Price Targets

A number of equities analysts have issued reports on CVS shares. UBS Group upped their target price on CVS Health from $60.00 to $62.00 and gave the company a “neutral” rating in a research report on Thursday, November 7th. TD Cowen increased their price objective on shares of CVS Health from $73.00 to $80.00 and gave the company a “buy” rating in a research note on Monday, November 25th. Mizuho dropped their target price on shares of CVS Health from $73.00 to $66.00 and set an “outperform” rating for the company in a research report on Thursday, October 24th. Barclays decreased their price target on CVS Health from $75.00 to $71.00 and set an “overweight” rating for the company in a research note on Thursday, November 7th. Finally, StockNews.com cut CVS Health from a “hold” rating to a “sell” rating in a research note on Thursday, November 14th. One analyst has rated the stock with a sell rating, six have issued a hold rating and thirteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, CVS Health presently has a consensus rating of “Moderate Buy” and a consensus price target of $68.71.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.